Biomarkers of tumour redox status in response to modulations of glutathione and thioredoxin antioxidant pathways

References

• Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006;10:241–252.
   PubMed Web of Science ®Google Scholar
• DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475:106–109.
   PubMed Web of Science ®Google Scholar
• Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780–783.
   PubMed Web of Science ®Google Scholar
• Balendiran GK, Dabur R, Fraser D. The role of glutathione in cancer. Cell Biochem Funct 2004;22:343–352.
   PubMed Web of Science ®Google Scholar
• Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL, et al. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009;390:191–214.
   PubMed Web of Science ®Google Scholar
• Lisbôa da Motta L, Müller CB, De Bastiani MA, Behr GA, França FS, da Rocha RF, et al. Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients. J Cancer Res Clin Oncol 2014;140:461–470.
   PubMed Web of Science ®Google Scholar
• Tsujikawa T, Asahi S, Oh M, Sato Y, Narita N, Makino A, et al. Assessment of the tumor redox status in head and neck cancer by 62Cu-ATSM PET. PLoS One 2016;11:e0155635.
   PubMedGoogle Scholar
• Dequanter D, Dok R, Nuyts S. Basal oxidative stress ratio of head and neck squamous cell carcinomas correlates with nodal metastatic spread in patients under therapy. Ott 2017;10:259–263.
   Google Scholar
• Bhatia M, McGrath KL, Di Trapani G, Charoentong P, Shah F, King MM, et al. The thioredoxin system in breast cancer cell invasion and migration. Redox Biol 2016;8:68–78.
   PubMed Web of Science ®Google Scholar
• Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087–3091.
   PubMed Web of Science ®Google Scholar
• Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003;142:46–51.
   PubMed Web of Science ®Google Scholar
• Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 2015;27:211–222
   PubMed Web of Science ®Google Scholar
• Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011;71:1385–1396.
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Zalupski MM, Conkling P, Nugent F, Ma WW, Modiano M, et al. A Phase 2 randomized, double-blind, multicenter trial of imexon plus gemcitabine versus gemcitabine plus placebo in patients with metastatic chemotherapy-naïve pancreatic adenocarcinoma. Am J Clin Oncol 2015. [Epub ahead of print]. DOI:10.1097/COC.0000000000000260
   PubMedGoogle Scholar
• Mitchell JB, Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer Suppl 1987;8:96–104.
   PubMedGoogle Scholar
• Biaglow JE, Lee I, Donahue J, Held K, Mieyal J, Dewhirst M, et al. Glutathione depletion or radiation treatment alters respiration and induces apoptosis in R3230Ac mammary carcinoma. Adv Exp Med Biol 2003;530:153–164.
   PubMed Web of Science ®Google Scholar
• Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, et al. A Phase I new approaches to neuroblastoma therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent/refractory high-risk neuroblastoma. Pediatr Blood Cancer 2016;63:1349–1356.
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996;14:249–256.
   PubMed Web of Science ®Google Scholar
• Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res 1995;15:4507–4511.
   Google Scholar
• Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, et al. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer 2015;62:1739–1746.
   PubMed Web of Science ®Google Scholar
• Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang N-H, et al. Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma. Clin Cancer Res 2016;22:3860–3875.
   PubMed Web of Science ®Google Scholar
• Triscott J, Rose Pambid M, Dunn SE. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram. Stem Cells 2015;33:1042–1046.
   PubMed Web of Science ®Google Scholar
• Bista R, Lee DW, Pepper OB, Azorsa DO, Arceci RJ, Aleem E, et al. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. J Exp Clin Cancer Res 2017;36:22.
   PubMed Web of Science ®Google Scholar
• Najlah M, Ahmed Z, Iqbal M, Wang Z, Tawari P, Wang W, et al. Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer. Eur J Pharm Biopharm 2017;112:224–233.
   PubMed Web of Science ®Google Scholar
• Daga M, Ullio C, Argenziano M, Dianzani C, Cavalli R, Trotta F, et al. GSH-targeted nanosponges increase doxorubicin-induced toxicity “in vitro” and “in vivo” in cancer cells with high antioxidant defenses. Free Radic Biol Med 2016;97:24–37.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, et al. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 2011;67:503–509.
   PubMed Web of Science ®Google Scholar
• Bradley KA, Zhou T, McNall-Knapp RY, Jakacki R, Levy AS, Vezina G, et al. Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children’s oncology group phase 2 study. Int J Radiat Oncol Biol Phys 2013;85:e55–e60.
   PubMed Web of Science ®Google Scholar
• Brachman DG, Pugh SL, Ashby LS, Thomas TA, Dunbar EM, Narayan S, et al. Phase 1/2 trials of temozolomide, motexafin gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. Int J Radiat Oncol Biol Phys 2015;91:961–967.
   PubMed Web of Science ®Google Scholar
• Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, et al. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget 2016;7:3548–3558.
   PubMedGoogle Scholar
• Topkas E, Cai N, Cumming A, Hazar-Rethinam M, Gannon OM, Burgess M, et al. Auranofin is a potent suppressor of osteosarcoma metastasis. Oncotarget 2016;7:831–844.
   PubMedGoogle Scholar
• You BR, Park WH. Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion. Oncol Rep 2016;35:546–551.
   PubMed Web of Science ®Google Scholar
• Celegato M, Borghese C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, et al. Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. Blood 2015;126:1394–1397.
   PubMed Web of Science ®Google Scholar
• Swartz HM, Khan N, Khramtsov VV. Use of electron paramagnetic resonance spectroscopy to evaluate the redox state in vivo. Antioxid Redox Signal 2007;9:1757–1771.
   PubMed Web of Science ®Google Scholar
• Hyodo F, Soule BP, Matsumoto K-I, Matusmoto S, Cook JA, Hyodo E, et al. Assessment of tissue redox status using metabolic responsive contrast agents and magnetic resonance imaging. J Pharm Pharmacol 2008;60:1049–1060.
   PubMed Web of Science ®Google Scholar
• Bakalova R, Zhelev Z, Aoki I, Saga T. Tissue redox activity as a hallmark of carcinogenesis: from early to terminal stages of cancer. Clin Cancer Res 2013;19:2503–2517.
   PubMed Web of Science ®Google Scholar
• Bačić G, Pavićević A, Peyrot F. In vivo evaluation of different alterations of redox status by studying pharmacokinetics of nitroxides using magnetic resonance techniques. Redox Biol 2016;8:226–242.
   PubMed Web of Science ®Google Scholar
• Emoto MC, Matsuoka Y, Yamada K-I, Sato-Akaba H, Fujii HG. Non-invasive imaging of the levels and effects of glutathione on the redox status of mouse brain using electron paramagnetic resonance imaging. Biochem Biophys Res Commun 2017;485:802–806.
   PubMed Web of Science ®Google Scholar
• Dooley CT, Dore TM, Hanson GT, Jackson W, Remington SJ, Tsien RY, et al. Imaging dynamic redox changes in mammalian cells with green fluorescent protein indicators. J Biol Chem 2004;279:22284–22293.
   PubMed Web of Science ®Google Scholar
• Roma LP, Duprez J, Takahashi HK, Gilon P, Wiederkehr A, Jonas J-C, et al. Dynamic measurements of mitochondrial hydrogen peroxide concentration and glutathione redox state in rat pancreatic β-cells using ratiometric fluorescent proteins: confounding effects of pH with HyPer but not roGFP1. Biochem J 2012;441:971–978.
   PubMed Web of Science ®Google Scholar
• de Souza AH, Santos LRB, Roma LP, Bensellam M, Carpinelli AR, Jonas J-C, et al. NADPH oxidase-2 does not contribute to β-cell glucotoxicity in cultured pancreatic islets from C57BL/6J mice. Mol Cell Endocrinol 2017;439:354–362.
   PubMed Web of Science ®Google Scholar
• Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969;27:502–522.
   PubMed Web of Science ®Google Scholar
• Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980;106:207–212.
   PubMed Web of Science ®Google Scholar
• Garcia J, Han D, Sancheti H, Yap L-P, Kaplowitz N, Cadenas E, et al. Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J Biol Chem 2010;285:39646–39654.
   PubMed Web of Science ®Google Scholar
• Hu J, Dong L, Outten CE. The redox environment in the mitochondrial intermembrane space is maintained separately from the cytosol and matrix. J Biol Chem 2008;283:29126–29134.
   PubMed Web of Science ®Google Scholar
• Østergaard H, Tachibana C, Winther JR. Monitoring disulfide bond formation in the eukaryotic cytosol. J Cell Biol 2004;166:337–345.
   PubMed Web of Science ®Google Scholar
• Kolossov VL, Hanafin WP, Beaudoin JN, Bica DE, DiLiberto SJ, Kenis PJA, et al. Inhibition of glutathione synthesis distinctly alters mitochondrial and cytosolic redox poise. Exp Biol Med (Maywood) 2014;239:394–403.
   PubMed Web of Science ®Google Scholar
• Rodman SlN, Spence JM, Ronnfeldt TJ, Zhu Y, Solst SR, O'Neill RA, et al. Enhancement of radiation response in breast cancer stem cells by inhibition of thioredoxin- and glutathione-dependent metabolism Radiat Res 2016;186:385–395.
   PubMed Web of Science ®Google Scholar
• Kim N-H, Park HJ, Oh M-K, Kim I-S. Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep 2013;46:59–64.
   PubMed Web of Science ®Google Scholar
• Meyer AJ, Dick TP. Fluorescent protein-based redox probes. Antioxid Redox Signal 2010;13:621–650.
   PubMed Web of Science ®Google Scholar
• Gallez B, Bacic G, Goda F, Jiang J, O′Hara JA, Dunn JF, et al. Use of nitroxides for assessing perfusion, oxygenation, and viability of tissues: in vivo EPR and MRI studies. Magn Reson Med 1996;35:97–106.
   PubMed Web of Science ®Google Scholar
• Epel B, Sundramoorthy SV, Krzykawska-Serda M, Maggio MC, Tseytlin M, Eaton GR, et al. Imaging thiol redox status in murine tumors in vivo with rapid-scan electron paramagnetic resonance. J Magn Reson 2017;276:31–36.
   PubMed Web of Science ®Google Scholar
• Kuppusamy P, Li H, Ilangovan G, Cardounel A, Zweier JL, Yamada K, et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 2002;62:307–312.
   PubMed Web of Science ®Google Scholar
• Ilangovan G, Li H, Zweier JL, Krishna MC, Mitchell JB, Kuppusamy P, et al. In vivo measurement of regional oxygenation and imaging of redox status in RIF-1 murine tumor: effect of carbogen-breathing. Magn Reson Med 2002;48:723–730.
   PubMed Web of Science ®Google Scholar
• Wolf AM, Nishimaki K, Kamimura N, Ohta S. Real-time monitoring of oxidative stress in live mouse skin. J Invest Dermatol 2014;134:1701–1709.
   PubMed Web of Science ®Google Scholar
• Wagener KC, Kolbrink B, Dietrich K, Kizina KM, Terwitte LS, Kempkes B, et al. Redox indicator mice stably expressing genetically encoded neuronal roGFP: versatile tools to decipher subcellular redox dynamics in neuropathophysiology. Antioxid Redox Signal 2016;25:41–58.
   PubMed Web of Science ®Google Scholar
• Bohndiek SE, Kettunen MI, Hu D-E, Kennedy BWC, Boren J, Gallagher FA, et al. Hyperpolarized [1–13C]-ascorbic and dehydroascorbic acid: vitamin C as a probe for imaging redox status in vivo. J Am Chem Soc 2011;133:11795–11801.
   PubMed Web of Science ®Google Scholar
• Keshari KR, Sai V, Wang ZJ, Vanbrocklin HF, Kurhanewicz J, Wilson DM. Hyperpolarized [1–13C]-dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET. J Nucl Med 2013;54:922–928.
   PubMed Web of Science ®Google Scholar